Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.4391
-0.0230 (-4.98%)
At close: Nov 5, 2026, 4:00 PM EST
0.4341
-0.0050 (-1.14%)
After-hours: Nov 5, 2026, 7:53 PM EST
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $8.70K in the quarter ending June 30, 2026, a decrease of -99.42%. In the fiscal year ending September 30, 2025, Outlook Therapeutics had annual revenue of $1.41M. That makes Outlook Therapeutics the 48,184th largest company in the world by revenue and 7,389th in the United States.
Revenue (ttm)
$1.41M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
106.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.41M | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | 8.15M | 5.06M | 163.84% |
| Sep 30, 2018 | 3.09M | -723.96K | -18.99% |
| Sep 30, 2017 | 3.81M | 831.94K | 27.92% |
| Sep 30, 2016 | 2.98M | -2.24M | -42.91% |
| Sep 30, 2015 | 5.22M | -3.83M | -42.33% |
| Sep 30, 2014 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Voyager Therapeutics | 25.11M |
| Armata Pharmaceuticals | 5.54M |
| Equillium | 4.39M |
| Humacyte | 2.12M |
OTLK News
- 27 days ago - Outlook Therapeutics announces Greg DiPasquale as chief commercial officer - TheFly
- 27 days ago - Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion - GlobeNewsWire
- 5 weeks ago - Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA - TheFly
- 5 weeks ago - Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 6 weeks ago - Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment - Business Wire
- 7 weeks ago - Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts